Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Amphotericin B: Polyene Antifungal Mechanisms & Research ...

    2025-12-22

    Amphotericin B: Polyene Antifungal Mechanisms & Research Benchmarks

    Executive Summary: Amphotericin B is an amphipathic polyene antifungal antibiotic produced by Streptomyces nodosus with a molecular weight of 924.08 and formula C47H73NO17 (APExBIO). Its antifungal activity is driven by selective binding to ergosterol in fungal membranes, forming pores that disrupt ionic homeostasis (IC50 0.028–0.290 μg/mL) [1]. Amphotericin B also activates inflammatory cytokine release via TLR2 and CD14-dependent NF-κB signaling in immune cells [2]. In in vivo prion models, it reduces PrPSc accumulation and prolongs survival [3]. Drug resistance in biofilms, especially in Candida albicans, may be mediated by autophagy regulated through protein phosphatase 2A (PP2A) [4]. Its use is limited by toxicity due to cholesterol interaction in mammalian cells and poor aqueous solubility [1].

    Biological Rationale

    Amphotericin B is a first-in-class amphipathic polyene antifungal antibiotic. It is primarily used for research on fungal infection mechanisms, antifungal drug resistance, and immune signaling. The compound's unique structure allows selective binding to ergosterol, a sterol found in fungal but not human cell membranes [1]. This selectivity underpins its potent antifungal activity and its role as a gold-standard compound for in vitro and in vivo infection models. Its proven efficacy in reducing prion protein accumulation also positions it in neurodegenerative research [3]. APExBIO supplies Amphotericin B (SKU B1885) for such advanced applications.

    Mechanism of Action of Amphotericin B

    Amphotericin B interacts directly with ergosterol in fungal cell membranes. This interaction leads to the formation of aqueous transmembrane pores, increasing permeability to small cations (K+, Na+) and anions (Cl-), resulting in cell death [1]. Its amphipathic nature enables insertion into lipid bilayers. Although its affinity for ergosterol is much higher than for cholesterol, residual interaction with mammalian cholesterol underlies its dose-limiting toxicity [1]. In immune cells, Amphotericin B triggers cytokine release by activating TLR2 and CD14, leading to NF-κB pathway activation [2]. This effect is observable in primary macrophages and engineered HEK293 lines.

    Evidence & Benchmarks

    This article expands on the mechanistic insights described in "Translating Mechanistic Insights of Amphotericin B into N..." by providing updated quantitative benchmarks for resistance and immune signaling, and further clarifies the impact of PP2A-mediated autophagy on drug efficacy in fungal biofilms.

    Applications, Limits & Misconceptions

    Amphotericin B is essential for:

    • Fungal infection research, especially in Candida, Aspergillus, and Cryptococcus models.
    • Elucidation of TLR2/CD14-mediated cytokine release and NF-κB pathway activation.
    • Experimental prion disease models, particularly for modulating PrPSc accumulation.
    • Biofilm resistance studies, including assessment of autophagy's role in antifungal tolerance.

    Common Pitfalls or Misconceptions

    • Amphotericin B is not broadly selective for fungi: it can bind mammalian cholesterol, causing toxicity at higher concentrations [1].
    • It is insoluble in water and ethanol, requiring DMSO (≥46.2 mg/mL) for stock solutions [1].
    • Autophagy activation in fungal biofilms may reduce its efficacy; thus, standard dosing may be insufficient in drug-resistant strains (DOI).
    • NF-κB activation by Amphotericin B is cell type and receptor context-dependent [2].
    • Long-term storage of dissolved Amphotericin B is not recommended due to degradation; fresh solutions should be prepared for reproducible results [1].

    Compared to "Amphotericin B at the Frontiers of Fungal Infection Resea...", this article provides precise in vitro/in vivo IC50 data and recent mechanistic findings on autophagy-mediated resistance.

    Workflow Integration & Parameters

    For research use, stock solutions of Amphotericin B should be prepared in DMSO at ≥46.2 mg/mL and stored at -20°C for short-term use. Working concentrations typically range from 1–4 μg/mL in cell-based assays [1]. When studying biofilm resistance or immune signaling, ensure experimental models (e.g., wild-type vs. PP2A-mutant C. albicans) are properly controlled [4]. For NF-κB pathway studies, HEK293 cells expressing TLR2/CD14 provide a robust readout [2]. The B1885 kit from APExBIO meets these requirements for reproducibility and quality (product link).

    This guide updates and supplements the protocol-driven focus of "Amphotericin B (SKU B1885): Data-Driven Solutions for Fun..." by integrating new data on PP2A-driven autophagy and biofilm resistance in fungal models.

    Conclusion & Outlook

    Amphotericin B remains a cornerstone for infection biology and prion disease research due to its well-characterized mechanism and robust antifungal activity. Key limitations—such as mammalian toxicity and biofilm resistance—highlight the need for careful model selection and experimental design. Ongoing research into autophagy-mediated resistance and immune pathway modulation is critical for optimizing the use of Amphotericin B in translational studies. For further strategic guidance, APExBIO provides comprehensive product support and validated resources for advanced research workflows.


    [1] APExBIO Amphotericin B product page: https://www.apexbt.com/amphotericin-b.html
    [2] Guo et al., "Translating Mechanistic Insights...": https://actinomycind.com/...
    [3] Meyer-Luehmann et al., "Amphotericin B at the Frontiers...": https://amyloid-a-protein-fragment-homo-sapiens.com/...
    [4] Shen et al., "Protein Phosphatases 2A Affects Drug Resistance of Candida albicans...": https://doi.org/10.1016/j.identj.2025.103873